Hologic
HOLX
About: Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Employees: 7,063
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 6 (+3) [Q2]
5% more capital invested
Capital invested by funds: $13.5B [Q1] → $14.2B (+$678M) [Q2]
0.4% more ownership
Funds ownership: 97.56% [Q1] → 97.96% (+0.4%) [Q2]
1% less first-time investments, than exits
New positions opened: 101 | Existing positions closed: 102
2% less funds holding
Funds holding: 695 [Q1] → 681 (-14) [Q2]
17% less repeat investments, than reductions
Existing positions increased: 223 | Existing positions reduced: 268
37% less call options, than puts
Call options by funds: $51.8M | Put options by funds: $82.7M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
|
RBC Capital
Conor McNamara
|
$87
|
Outperform
Upgraded
|
6 Aug 2025 |
|
Morgan Stanley
Tejas Savant
|
$69
|
Equal-Weight
Maintained
|
31 Jul 2025 |
|
UBS
Elizabeth Garcia
|
$70
|
Neutral
Maintained
|
31 Jul 2025 |
|
Mizuho
Anthony Petrone
|
$70
|
Outperform
Maintained
|
16 Jul 2025 |
|
Citigroup
Patrick Donnelly
|
$80
|
Buy
Upgraded
|
9 Jul 2025 |
|
Evercore ISI Group
Vijay Kumar
|
$68
|
In-Line
Maintained
|
8 Jul 2025 |
Financial journalist opinion
Based on 12 articles about HOLX published over the past 30 days
